Litchfield Hills Research Produced their USAQ Q3 2020 Research Report on December 14, 2020
USAQ is rated as a BUY with a Price Target of $5 per share.
United States Equities Corp (Stock symbol USAQ) has been identified by Litchfield Hills Research as an "attractive" opportunity for those interested in the digital medicine space. With stocks currently trading under $1, the research group rates USAQ as a BUY with a target price of $5 per share.
USAQ’s solely owned subsidiary, Medical Practice Income has developed a unique, cloud-based, medical office and mobile patient education digital medicine platform designed to generate new medical practice income for the physician and improve clinical outcomes for the patient.
“USAQ’s is an attractive valuation. The shares appear to us inexpensive on an absolute and relative basis.”
SUMMARY
• USAQ reported 3Q20 which was generally in-line with expectations. It reported a loss of $0.01 EPS on no revenue. We were looking for a loss of $0.01 EPS also on no revenue. On the margin, expenses were higher than expected but not by enough to change the results.
• Medical Practices Income (MPI) has developed a unique, cloud-based, medical office and mobile patient education digital medicine platform designed to generate new medical practice income for the physician and improve clinical outcomes for the patient.
• The COVID-19 Pfizer vaccine has recently shown there are serious side effects among people with severe allergies. MPI is positioned with its AllegiEnd® allergy test kits which could be used to screen patients for severe allergies by physicians and NPs that are not allergy specialists.
• We have increased the operating expenses in the model consistent with 3Q20 and between that and 4Q20, our 2020 EPS loss goes to $0.05 from $0.04. No change to other estimates.
• Attractive valuation. The shares appear to us inexpensive on an absolute and relative basis.